Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia

Journal of Hypertension

Volumn 19, Issue 4, 2001, Pages 749-755

  Jonkers, Iris J ^a,b   De Man, Frits H ^a,b   Van Der Laarse, Arnoud ^a,b   Frölich, Marijke ^a,b   Gevers Leuven, Jan A ^a,b   Kamper, Ad M ^a,b   Blauw, Gerard J ^a,b   Smelt, Augustinus H ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Blood pressure; Endothelin; Endothelium; Hypertriglyceridemia

Indexed keywords

BEZAFIBRATE; CATECHOLAMINE; CYCLIC GMP; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035072138     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200104000-00012     Document Type: Article

References (37)

1. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
2. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome
3. Secondary prevention by raisin9 HDL cholesterol and reducing triglycerides in patients with coronary artery disease
4. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
5. Lowering fibrinogen levels: Clinical update. Bezafibrate infarction prevention
6. Acute effects of bezafibrate on blood pressure and renal haemodynamics in SHR and WKY rats
7. Treatment of essential hypertension and hypercholesterolemia with or without hypertriglyceridemia, with low dose of bezafibrate (200 mg/day)
8. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation
9. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance
10. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man
11. Nonesterified fatty acids in the pathogenesis of hypertension: Theory and evidence
12. Renal handling of insulin in man
13. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients
14. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
15. The L-arginine-nitric oxide pathway
16. Determination of oatecholamines in human plasma by high-performance liquid chromatography: Comparison between a new method with fluorescence detection and an established method with electrochemical detection
17. Radioimmunoassay for cyclic nucleotides. Preparation of antibodies and iodinated cyclic nucleotides
18. Relation between systemic hypertension and blood lipids on the risk of myocardial infarction
19. The Prospective Cardiovascular Munster Study: Prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension
20. Hypertension, dyslipidemia, and insulin resistance: Links in a chain or spokes on a wheel?
21. Effects of insulin on growth of cultured arterial smooth muscle cells
22. Fatty acids enhance vascular alpha-adrenergic sensitivity
23. Mechanisms in the pressor effects of hepatic portal venous fatty acid infusion
24. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators
25. Pathophysiology of insulin resistance in human disease
26. Improved insulin sensitivity by bezafibrate in rats: Relationship to fatty acid composition of skeletal-muscle triglycerides
27. Suppression of endothelin-3-induced nitric oxide synthesis by triglyceride in human endothelial cells
28. Endothelial nitric oxide production and insulin sensitivity: A physiological link with implications for pathogenesis of cardiovascular disease
29. Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilatation: Reversal after lipid-lowering therapy by atorvastatin
30. Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity
31. Chronic selective hypertriglyceridemia impairs endothelium-dependent vasodilatation in rats
32. Normal oxidative stress and enhanced lipoprorein resistance to in vitro oxidation in hypertriglyceridemia. Effects of bezafibrate therapy
33. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus
34. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans
35. Insulin-induced endothelin release and vasoreactivity in hypertriglyceridemic and hypertensive rats
36. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
37. Effect of HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia